In the published article, there was an error. The ClinicalTrials.gov-identifier of our study was not included in the publication.
A correction has been made to Materials and methods, Reporting guidelines and ethics, Paragraph 1. This sentence previously stated:
“The study was approved by the Regional Ethics Committee of Norway South-East D (Reference number 485084)”.
The corrected sentence appears below:
“The study was approved by the Regional Ethics Committee of Norway South-East D (Reference number 485084) and registered at http://ClinicalTrials.gov (Reference number NCT05834348)”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
ROS, ALK, EGFR, real world data, lung cancer, time on treatment
Citation
Nyen JE, Booth AØ, Husby Ø, Bugge C, Engebretsen I, Oteiza F, Helland Å, Fjellbirkeland L, Brustugun OT and Grønberg BH (2025) Corrigendum: Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients – a nationwide and longitudinal study. Front. Oncol. 15:1595028. doi: 10.3389/fonc.2025.1595028
Received
17 March 2025
Accepted
18 March 2025
Published
26 March 2025
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
15 - 2025
Updates
Copyright
© 2025 Nyen, Booth, Husby, Bugge, Engebretsen, Oteiza, Helland, Fjellbirkeland, Brustugun and Grønberg.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Johanne Elise Nyen, jen@osloeconomics.no
†Present address: Anja Ødegård Booth, AstraZeneca AS, Oslo, Norway
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.